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Abstract
Background: We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with
systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score
(PSDSS) on outcomes.
Methods: One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years
1987-2006 were identified from a prospective institutional database. These patients either received no
chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according
to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was
performed using the Kaplan-Meier method and comparison with the log-rank test.
Results: Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months
(95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated
with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy
compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an
independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001].
Conclusion: A trend towards improved outcomes is demonstrated from treatment of patients with PC from
colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection
and prognostication in PC of colorectal origin.
Background
The majority of patients with peritoneal carcinomatosis
(PC) from colorectal cancer present with unresectable
disease at the time of diagnosis. The morbid nature and
fatality peritoneal disease in patients with colorectal can-
cer is significant and the recent focus of clinical out-
comes research. In a recent multi-centre prospective
study of 370 patients with PC from non-gynecological
malignancies, patients with colorectal cancer survived a
median time of 5.2 months [1]. Research protocols
using palliative systemic chemotherapy for PC have
been conducted with encouraging tumor response rates,
but overall survival remains poor [2,3]. The reported
median survival after systemic 5-Fluorouracil/Leucov-
orin (5FU/L) based chemotherapy for PC of colorectal
cancer can, under the best of circumstances, achieve
median survival of only 5.2 to 12.6 months [4].
Modern systemic therapy regimens with combinations
of cytotoxic and biological agents appear promising in
clinical trials, demonstrating improved tumor response
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gains in both progression-free and overall survival in
patients with metastatic colorectal cancer [5-10]. None-
theless, the patient cohorts with Stage IV disease in
these trials have failed to include patients with PC. The
difficulties of including these patients are a result of the
inability to image sub-centimetre peritoneal lesions and
assess tumor response on the RECIST criteria. Hence,
strictly speaking, this leaves this subgroup of patients
with Stage IV colorectal cancer without any appreciable
evidence of disease and the treatment response cannot
be documented or monitored.
Aggressive surgical therapy has been shown to be pro-
mising when combined with hyperthermic intraperito-
neal chemoperfusion (HIPEC). A multi-institutional
registry study of 506 patients with PC of colorectal ori-
gin showed that median survival of up to 32 month can
be attained with this aggressive multi-modality treat-
ment approach in patients with limited peritoneal sur-
face disease who are able to undergo complete
cytoreduction [11]. More recently, Elias et al reported a
5-year survival rate of 51% and median survival of 63
months in patients with limited PC treated with oxali-
platin-based HIPEC [12].
The lack of specific data for patients with isolated PC
represents a gap in the current literature. In the modern
era of effective systemic chemotherapy, outcomes for
this particular patient subset (limited PC of colorectal
origin) need to be re-examined. Further, the consider-
able progress made in CS and HIPEC in peritoneal car-
cinomatosis has not rightfully translated into routine
clinical practice. Debate over the appropriateness of CS
and HIPEC as a treatment strategy without concrete
and replicable data from randomized trials, together
with concerns over aggregate treatment-related morbid-
ity and mortality ranging from 14% to 55% and 0% to
19%, respectively [4], have hampered the ability to reach
a treatment consensus amongst the general oncology
community. To evaluate the effectiveness of systemic
chemotherapy, we report the results of a single institu-
tion experience of systemic chemotherapy for PC from
colorectal cancer with stratification according to the
peritoneal surface disease severity score (PSDSS) to elu-
cidate stage-specific outcomes that may guide clinical
treatment decision for patient-specific delivery of
therapy.
Methods
Cohort Definition
Between January 1 1987 and December 31 2006,
patients with colorectal cancer treated at the University
of Wuerzburg Medical Centre were identified from the
Wuerzburg Institutional Database (WID). In our institu-
tion, the surgical peritoneal surface malignancies
program (including debulking surgery and HIPEC) was
initiated in September 2008. Patients were included if
they had intraoperatively confirmed peritoneal carcino-
matosis either at the time of initial presentation or at
time of recurrence with histological diagnosis of tumor
from colorectal origin. The exclusion criteria were for
peritoneal carcinomatosis from non-colorectal origin,
patients died within 30 days after exploration or having
more than three extra abdominal metastases.
Data Source
The WID is a central data repository that is expanded
prospectively on a daily basis with clinical, operative,
and research data of patients who were evaluated and
treated at the University of Wuerzburg Medical Cen-
tre. Data available within the WID include patient
demographics, histological diagnoses that are based on
International Classification of Diseases coding stan-
dards, physician and hospital billing data, inpatient
admission and outpatient registration data, operating
room procedures, laboratory results, and computerized
pharmacy records. The WID undergoes continuous
cross platform integration with the Comprehensive
Cancer Registry to ensure updated follow-up informa-
tion for identification of deceased patients. Inpatient
and outpatient records of all identified patients were
reviewed retrospectively to extract information regard-
ing type and duration of chemotherapy, sites of meta-
static disease at presentation and disease status at last
follow-up.
Retrospective Peritoneal Surface Disease Severity Score
(PSDSS)
The retrospective PSDSS was estimated based on the
three most important prognostic indicators; clinical
symptoms, extent of carcinomatosis based on the tumor
burden (analog PCI) and tumor histopathology [13].
Each of these three categories was classified into three
sub-categories based on the severity of each clinico-
pathological factor:
1. Clinical Symptoms; none, mild (weight loss < 10%
of body weight, mild abdominal pain, asymptomatic
ascites) or severe (weight loss ≥10% of body weight,
unremitting pain, bowel obstruction, symptomatic
ascites).
2. Extent of Carcinomatosis intraoperatively; limited
(analog PCI < 10), moderate (analog PCI 10 to 20)
or extensive (analog PCI > 20).
3. Tumor histopathology of the primary tumor; well
to moderately differentiated without positive lymph
node, moderately differentiated with positive lymph
nodes or poorly differentiated and/or signet ring
(Table 1).
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derived from the patient’s clinical presentation at the
time of evaluation for treatment, radiological assessment
of the extent of carcinomatosis, and the tumor histo-
pathology. This was scored as stages I to IV based on
the summation of the arbitrary scores for each of the
three clinicopathological staging parameters based on
our clinical experience: PSDSS Stage I < 4; PSDSS Stage
II = 4-7; PSDSS Stage III = 8-10; PSDSS Stage IV > 10.
Follow-Up and Outcomes
Treatment was grouped according to the type of sys-
temic chemotherapy regimen; no chemotherapy (best
supportive care), 5-Fluorouracil/Leucovorin (5FU/L), or
modern chemotherapy (Oxaliplatin/Irinotecan-based)
with or without biological agents (Bevacizumab/Cetuxi-
mab/Panitumumab). All patients were followed every
3 months. Helical contrast enhanced computed tomo-
graphy (CT) was performed every 6 months. Follow-up
data was obtained from the referring physicians, phone
calls and/or emails from the patients, or the cancer reg-
istry. All deaths in this study were disease-related, attri-
butable to progressive colorectal cancer. The primary
study endpoint was from the time of diagnosis of perito-
neal carcinomatosis to the time of death (overall survi-
val). Follow-up data recorded included the data of the
status of the patient (alive with disease, alive without
disease and dead of disease).
Statistics
The data collected were analyzed using JMP software
(JMP® , Cary, NC Version 7) software. The patient char-
acteristics were reported using frequency and descriptive
analyses. The Kaplan-Meier method was used to analyze
survival. Univariate analysis (log-rank) was performed to
determine the clinicopathological factors affecting survi-
val, including the PSDSS stage. All factors correlating
with outcome having p < 0.10 on univariate were
entered into a Cox proportional hazards regression
model for multivariate analysis. The median time to
death was defined as the time where 50% of patients
have died. P < 0.05 was considered statistically
significant.
Results
Patient Characteristics
O n et h o u s a n dn i n eh u n d r e da n dt w e n t yp a t i e n t sw i t h
colorectal cancer underwent a laparotomy during the
study period. Peritoneal carcinomatosis was observed
in 240 patients (13%); 98 patients (42%) at initial
diagnosis and 142 patients (58%) at time of recur-
rence. Ten patients (2%) died from surgical complica-
tions during the immediate post operative period,
eight patients (3%) died prematurely of non-cancer
related reasons, 20 patients (8%) had incomplete
records in the database, and 35 patients (15%) with
more than 3 extra abdominal metastasis were
excluded from study. In total, 167 patients formed the
cohort of this study.
The median age was 63 (range, 22 to 88) years. Sixty-
four patients (38%) had isolated peritoneal carcinomato-
sis. Aside from peritoneal carcinomatosis, other sites of
metastasis include the liver or lung in 67 patients (40%)
and 36 patients (22%) had peritoneal carcinomatosis
with bone or brain metastasis. The detailed patient char-
acteristics are presented in Table 2.
Survival Analysis
The median follow-up time from diagnosis of peritoneal
carcinomatosis to last clinical follow up was 8 (range,
1 to 112) months. At the time of analysis, 163 patients
(98%) have died of disease and there were four survivors
(2%) who are alive without disease. The median follow-
up in these four survivors was 78 (range, 43 to 112)
months. The overall median survival was 8 (95%CI 6 to
9) months and the 3- and 5-year overall survival was 6%
and 3% respectively (Figure 1).
Impact of Chemotherapy Treatment on Outcomes
Eighty-three patients (50%) had no chemotherapy treat-
ment and received best supportive care only. Forty-two
patients (25%) received 5FU/L chemotherapy and forty-
two patients (25%) received modern chemotherapy of
which eight patients (5%) had biological agents in com-
bination with modern chemotherapy. The median dura-
tion of chemotherapy treatment was 18 (range, 0 to
115) weeks.
Table 1 Estimation of Peritoneal Surface Disease Severity of Patients with Colorectal Cancer Peritoneal Carcinomatosis
Peritoneal Surface Disease Severity Score for Colorectal Cancer
Clinical Symptoms Extent of Carcinomatosis Primary Tumor Histopathology
No Symptoms PCI < 10 Well or Moderately Differentiated and N0
0 points 1 Point 1 Point
Mild Symptoms PCI 10 to 20 Moderately Differentiated and N1 or N2
1 Point 3 Points 3 Points
Severe Symptoms PCI > 20 Poorly Differentiated or Signet Ring
6 Points 7 Points 9 Points
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patients receiving best supportive care, 11 (95%CI 6 to
15) months for patients treated with 5 FU/L, and 12
(95%CI 4 to 20) months for patients treated with mod-
ern chemotherapy. The median survival differed signifi-
cantly in patients who received chemotherapy versus
those who received best supportive care (p = 0.026),
however, outcomes did not differ between patients trea-
ted with 5FU/L or modern chemotherapy (p > 0.05)
(Figure 2).
Stratifications According to the retrospective PSDSS
Six patients (4%) were scored as PSDSS Stage I, 53
patients (32%) as PSDSS Stage II, 33 patients (20%) as
PSDSS Stage III and 75 patients (45%) as PSDSS Stage
IV. The detailed treatment type in patients classified
according to the PSDSS is shown in Table 3. Treatment
differed between the four PSDSS Stages (p = 0.02).
Median survival differed stage-wise was 4 (95%CI 2.7 -
5.1) months for PSDSS Stage IV, 7 (95%CI 4.4 - 10.3)
months for PSDSS Stage III, 19 (95%CI 13.8 - 24.1)
months for PSDSS Stage II, and 39 (95%CI 34.2 - 42.4)
months for PSDSS Stage I (p = 0.003) (Figure 3). The
median survival of all patients with PSDSS Stage I/II
was 22 (95%CI 14.2 - 26.7) months and for PSDSS Stage
III/IV was 5 (95%CI 4.2 - 7.2) (p < 0.001) (Figure 4).
In the PSDSS Stage I/II patients (n = 59) who received
best supportive care, the median survival was 16 (95%CI
12.8 - 24.0) months; for those who received 5FU/L, the
median survival was 16 (95%CI 13.7 - 22.8) months, and
for patients treated with modern systemic chemother-
apy, the median survival was 28 (95%CI 17.1 - 38.2)
months (p = 0.12) (Figure 5). For a subgroup of patients
with isolated PC with PSDSS Stage I/II (n = 20), the
median survival was 21 (95%CI 16.6 - 24.8) and not dif-
ferent compared to the whole group.
Analysis of overall survival from diagnosis of carcino-
matosis to last follow-up in uni- and multivariate ana-
lyze is shown in Table 4
Discussion
Cytoreductive surgery (CS) combined with intraopera-
tive hyperthermic intraperitoneal chemotherapy
(HIPEC) is a treatment option for selected patients with
peritoneal carcinomatosis (PC) from colorectal cancer.
There has been enormous interest in the literature
about this multi-modality therapeutic approach for a
disease that has been associated with poor outcome.
Phase II studies have demonstrated that CS combined
with HIPEC is associated with an improved survival in
patients with limited PC amenable to complete cytore-
d u c t i o nw h e nc o m p a r e dt oh i s t o r i c a lc o n t r o l sw h i c h
were treated palliatively with systemic chemotherapy
alone [14]. In 2004, a multi-institutional registry from
28 international treatment centres demonstrated that
the median survival was 19 months and 3-year survival
was 39% in 506 patients with CRPC who were treated
with CS and HIPEC. These early outcomes are encoura-
ging; however, treatment-related morbidity and mortal-
ity contribute to continued concern over the feasibility
of this aggressive multi-modality therapy approach [11].
With continued specialty-centre experience, the patient
selection process has improved. A recently published
consensus statement emphasized the critical importance
of proper patient selection to identify only suitable can-
didates for treatment to ensure that appropriately
selected candidates receive and benefit from treatment,
and unsuitable candidates are not subjected to the mor-
bidity of a procedure unlikely to improve patient out-
come [15].
By redefining and optimizing the patient selection pro-
cess, treatment of patients with only limited PC has
been shown to provide potentially curative oncological
treatment. Elias et al. reported in a comparative trial a
median survival of 62.7 months for patients with limited
PC treated with CS and HIPEC compared to a median
survival of 23.9 months in patients treated with pallia-
tive surgery and systemic chemotherapy alone [12].
Although, the survival results in this study reflect a
highly selected group of patients, the impressive survival
Table 2 Characteristics of patients with peritoneal surface
malignancy of colonic origin (n = 167)
Characteristics N % of Total
Male 93 56
Age < 50 Years 74 44
Mean Age (Years ± SD) 63 ± 17
Disease Presentation
Synchronous 52 33
Metachronous 115 67
Location
Colon 123 73
Rectum 44 27
Site of Metastases
Peritoneum Only 64 38
Peritoneum+Lung/Liver 67 40
Peritoneum+Other 36 22
Systemic Chemotherapy
None 83 50
5FU/L 42 25
Modern 42 25
PSDSS Stage
Stage I 6 4
Stage II 53 31
Stage III 33 20
Stage IV 75 45
Pelz et al. BMC Cancer 2010, 10:689
http://www.biomedcentral.com/1471-2407/10/689
Page 4 of 12results support the concept that CS/HIPEC is a poten-
tially curative treatment strategy and if performed in
patients with limited PC, cure can be attained with high
likelihood. If the extent of PC is not controlled through
complete cytoreduction, CS and HIPEC may still
prove beneficial; however, its role in the current era of
modern systemic chemotherapy may require further
investigation.
 
Figure 1 Survival of 167 patients with isolated peritoneal carcinomatosis or peritoneal carcinomatosis as a combined site of disease
with less than two other metastatic sites.
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Page 5 of 12Figure 2 Survival stratified by type of chemotherapy treatment (no chemo vs. 5FU/L and modern systemic chemotherapy; p = 0.026).
Table 3 Analysis of chemotherapy treatment by PSDSS staging
Chemotherapy Treatment PSDSS Stage I (n = 6) PSDSS Stage II (n = 53) PSDSS Stage III (n = 33) PSDSS Stage IV (n = 75)
Best Supportive Care 4 15 12 52
5FU/L 1 19 10 12
Modern Systemic Chemotherapy 1 19 11 11
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a r es u i t a b l ec a n d i d a t e sf o rC S / H I P E C ,P e l ze ta lp r o -
posed and validated a scoring system (Peritoneal Surface
Disease Severity Score) that stages patients with PC tak-
ing into consideration the clinicopathological markers
that predict for treatment outcome [13]. In an analysis
of patients who underwent a complete cytoreduction,
patients who were staged as PSDSS Stage I and Stage II
were shown to have a 3-year overall survival of 60% to
80%. Although the study was limited by the follow-up
Figure 3 Survival according to Peritoneal Surface Disease Severity Score Stage I to IV.
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outlook depicted in the Kaplan-Meier curve showed a
trend towards long-term survival [16].
In the present study, we used a retrospective
PSDSS, because the PCI, described by Sugarbaker,
was published first in 1995. The retrospective evalua-
tion of the PCI is very difficult. For this reason, we
used the term low, moderate and extensive to
describe the tumor burden, analog to the PCI <10,
11-20 and > 20.
Figure 4 Survival stratified by PSDSS Stage I/II, PSDSS Stage III and PSDSS Stage IV.
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that peritoneal carcinomatosis is a foremost cause of
disease-specific mortality in patients with metastatic col-
orectal cancer. Patients with isolated PC, PC with liver/
lung metastasis, or PC with brain/bone metastasis, pre-
dictably experienced early demise (p = 0.15), with an
overall median survival of 5.0 months. The poor survival
results reflect a subgroup of patients observed routinely
Figure 5 Survival stratified by PSDSS Stage I/II by no chemotherapy, 5FU/L, modern combination systemic chemotherapy (no chemo
v.s. 5FU/L and combination.
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ited. The biologically aggressive nature of PC impairs
the functional status of patients to an extent that makes
them eligible only for palliative, best supportive care
only. It also remains unfortunate that, although modern
systemic chemotherapy have improved survival in
patients with metastatic colorectal cancer, the analysis
in our study did not show a difference in outcomes
between treatment with 5FU/L compared to modern
chemotherapy in patients with PC (Figure 2). However,
the authors do acknowledge that the number of patients
receiving modern systemic chemotherapy, especially in
combination with biological agents, in the current study
are small, and further studies involving a larger cohort
Table 4 Analysis of overall survival from diagnosis of carcinomatosis to last follow-up in 167 patients with peritoneal
carcinomatosis of colonic origin
Characteristics n Median Survival (Months) P (Univariate) P (Multivariate)
RR [CI]
Sex 0.45
Male 93 8
Female 74 8
Age (Years) 0.58
<6 0 8 5 8
≥ 60 82 8
Disease Presentation 0.45
Synchronous 52 7
Metachronous 115 8
Location 0.07
Colon 123 8
Rectum 44 7
Site of Metastases 0.15
Peritoneum Only 64 7
Peritoneum+Lung/Liver 67 8
Peritoneum+Other 36 9
Systemic Chemotherapy 0.003
None 83 5
5FU/L 42 11
Modern 42 12
Clinical Symptoms < 0.001
Asymptomatic 55 18
Mild 78 6
Severe 34 3
Extent of Carcinomatosis 0.002
PCI < 10 103 6
PCI 10 to 20 47 11
PCI > 20 17 4
Histopathology 0.003
Well Differentiated 19 7
Moderately Differentiated 89 11
Poorly Differentiated/Signet 59 6
PSDSS Stage 0.003 0.001
Stage I 6 39 2.1 [1.3 - 4.9]
Stage II 53 19
Stage III 33 7
Stage IV 75 4
PSDSS Stage < 0.001 <0.001
Stage I/II 59 22 2.8 [1.5 - 5.4]
Stage III/IV 108 5
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effects.
By demonstrating a stage-wise difference in survival
stratified according to the PSDSS, it appears that this
staging system is of clinically meaningful prognostic uti-
lity in patients with peritoneal carcinomatosis. It is
important to emphasize the marked contrast in survival
outcomes between patients with PSDSS stage I/II and
stage III/IV PC. Further, in patients with isolated PC
who are PSDSS stage I/II, the median survival was 21
months. This survival result is comparable to current
survival data from randomized trials of metastatic color-
ectal cancer that encompasses the use of modern sys-
temic chemotherapy in combination with biological
agents [17-19]. To draw upon the favourable prognosis
of this group of patients, it is likely that patients with no
symptomatology, low volume peritoneal disease, and
favourable tumor biology, may derive the maximal bene-
fits of the effective CS/HIPEC treatment strategy.
Conclusions
In conclusion, our data demonstrates that peritoneal
carcinomatosis remains a fatal condition in patients with
metastatic colorectal cancer and it appears to be the
dominant determinant of outcome. Treatment with sys-
temic chemotherapy, especially modern agents is likely
to be beneficial in patients with PC of colorectal origin.
The optimal treatment results based on current evidence
may be attained through careful selection of patients
with a “favourable prognosis” for multi-modality therapy
in whom the benefits of treatment outweigh the asso-
ciated risks, for example, patients with PSDSS stage I/II,
to undergo radical surgical cytoreduction in combina-
tion with hyperthermic intraperitoneal chemotherapy in
an effort to obtain potentially curative disease clearance
and extend the overall survival.
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